

November 25, 2024

**FILED VIA SEDAR**

**British Columbia Securities Commission**

P.O. Box 10142, Pacific Centre  
9<sup>th</sup> Floor, 701 West Georgia Street  
Vancouver, BC V7Y 1L2

**Alberta Securities Commission**

Suite 600, 250 – 5<sup>th</sup> Street SW  
Calgary, AB T2P 0R4

**Ontario Securities Commission**

20 Queen Street West, 20<sup>th</sup> Floor  
Toronto, ON M5H 3S8

**Manitoba Securities Commission**

500 – 400 St. Mary Avenue  
Winnipeg, MB R3C 4K5

Dear Sirs/Mesdames:

**Re: Onco-Innovations Limited (the "Company")**

We refer to the prospectus of the Company dated November 25, 2024 relating to an offering of a minimum of 3,000,000 units at \$0.50 per unit for proceeds of \$1,500,000 and up to a maximum of 5,000,000 units at \$0.50 per unit for proceeds of \$2,500,000.

We consent to being named and to the use, through incorporation by reference in the above-mentioned prospectus, of our report dated July 29, 2024 to the shareholders of the Company on the following financial statements:

- Statements of financial position as at April 30, 2024 and 2023;
- Statements of loss and comprehensive loss, changes in equity and cash flows for the years ended April 30, 2024 and 2023.

We report that we have read the prospectus and all information specifically incorporated by reference therein and have no reason to believe that there are any misrepresentations in the information contained therein that are derived from the financial statements upon which we have reported or that are within our knowledge as a result of our audit of such financial statements. We have complied with Canadian generally accepted standards for an auditor's consent to the use of a report of the auditor included in an offering document, which does not constitute an audit or review of the prospectus as these terms are described in the CPA Canada Handbook – Assurance.

Yours truly,



SATURNA GROUP CHARTERED PROFESSIONAL ACCOUNTANTS LLP